Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate

Arthritis and Rheumatism

Volumn 62, Issue 11, 2010, Pages 3154-3160

  Gerlag, Daniëlle M ^a   Hollis, Sally ^b   Layton, Mark ^b   Vencovský, Jiří ^c   Szekanecz, Zoltán ^d   Braddock, Martin ^b   Tak, Paul P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ASTRAZENECA   (United Kingdom)

^c INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 5672; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; ETANERCEPT; METHOTREXATE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMOTAXIS; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; EX VIVO STUDY; FEMALE; HEADACHE; HUMAN; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BENZENEACETAMIDES; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; RECEPTORS, CCR5; SULFONAMIDES; TREATMENT OUTCOME;

EID: 77958503962     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27652     Document Type: Article

References (17)

1. Haringman J, Ludikhuize J, Tak PP,. Chemokines in joint disease: the key to inflammation? Ann Rheum Dis 2004; 63: 1186 - 94.
2. Katschke KJ Jr, Rottman JB, Ruth JH, Qin S, Wu L, LaRosa G, et al. Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocyte/macrophages in rheumatoid arthritis. Arthritis Rheum 2001; 44: 1022 - 32.
3. Patel DD, Zachariah JP, Whichard LP,. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001; 98: 39 - 45.
4. Suzuki N, Nakajima A, Yoshino S, Matsushima K, Yagita H, Okumura K,. Selective accumulation of CCR5+ T lymphocytes into inflamed joints of rheumatoid arthritis. Int Immunol 1999; 11: 553 - 9.
5. Haringman JJ, Smeets TJ, Reinders-Blankert P, Tak PP,. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis 2006; 65: 294 - 300.
6. Prahalad S,. Negative association between the chemokine receptor CCR5-32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun 2006; 7: 264 - 8.
7. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F,. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498 - 502.
8. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727 - 35.
9. Prevoo ML, van 'tHof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44 - 8.
10. Van Gestel AM, Prevoo ML, van 'tHof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34 - 40.
11. Bruce B, Fries JF,. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005; 23: S14 - 8.
12. Ware JE Jr, Sherbourne CD,. The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473 - 83.
13. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A,. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997; 36: 551 - 9.
14. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478 - 86.
15. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 353 - 63.
16. + T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis. Scand J Rheumatol 2007; 36: 428 - 33.
17. Fleishaker D, Wang X, Menon S, Zeiher BG, Stock TC,. A phase 2 study to assess the efficacy and safety of maraviroc, a CCR-5 antagonist in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 2009; 60 Suppl: S146.